Log in

ADC Therapeutics Stock Forecast, Price & News

+0.24 (+0.67 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $35.85
50-Day Range
MA: $31.87
52-Week Range
Now: $35.85
Volume89,996 shs
Average Volume216,091 shs
Market Capitalization$2.47 billion
P/E RatioN/A
Dividend YieldN/A
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Phone41 21 653 02 00



Sales & Book Value

Annual SalesN/A
Book Value$5.46 per share



Market Cap$2.47 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableNot Optionable
+0.24 (+0.67 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ADC Therapeutics (NYSE:ADCT) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of ADC Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ADC Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than ADC Therapeutics?

Wall Street analysts have given ADC Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ADC Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ADC Therapeutics' next earnings date?

ADC Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for ADC Therapeutics

What price target have analysts set for ADCT?

5 brokers have issued 12-month price targets for ADC Therapeutics' stock. Their forecasts range from $42.00 to $52.00. On average, they expect ADC Therapeutics' stock price to reach $46.50 in the next year. This suggests a possible upside of 29.7% from the stock's current price.
View analysts' price targets for ADC Therapeutics

Who are some of ADC Therapeutics' key competitors?

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include Honeywell International (HON), CVS Health (CVS), Raytheon Technologies (RTX), The Home Depot (HD), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

Who are ADC Therapeutics' key executives?

ADC Therapeutics' management team includes the following people:
  • Dr. Christopher J. Martin, Co- Founder, CEO & Director (Age 62)
  • Mr. Michael Forer L.L.B., Vice Chairman, Exec. VP & Gen. Counsel (Age 55)
  • Ms. Jennifer Creel, Chief Financial Officer (Age 49)
  • Mr. Robert A. Schmidt, VP, Corp. Controller & Chief Accounting Officer (Age 43)
  • Amanda Hamilton, Investor Relations Officer
  • Ms. Susan Romanus, Chief Compliance Officer (Age 55)
  • Mr. Peter Greaney Ph.D., Head of Corp. Devel. (Age 41)
  • Ms. Kimberly Pope, Sr. VP & Chief HR Officer (Age 54)
  • Dr. Patrick Van Berkel, Sr. VP of R&D (Age 52)
  • Dr. Jay M. Feingold M.D., Ph.D., Chief Medical Officer, Head of Oncology Clinical Devel. & Sr. VP (Age 64)

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an initial public offering on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO.

What is ADC Therapeutics' stock symbol?

ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT."

When did the company's lock-up period expire?

ADC Therapeutics' lock-up period expired on Wednesday, November 11th. ADC Therapeutics had issued 12,245,631 shares in its IPO on May 15th. The total size of the offering was $232,666,989 based on an initial share price of $19.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (3.03%), WINTON GROUP Ltd (0.33%), Principal Financial Group Inc. (0.31%), BlackRock Inc. (0.24%), ExodusPoint Capital Management LP (0.12%) and UBS Asset Management Americas Inc. (0.12%).

Which major investors are selling ADC Therapeutics stock?

ADCT stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., and Morgan Stanley.

Which major investors are buying ADC Therapeutics stock?

ADCT stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., ExodusPoint Capital Management LP, Principal Financial Group Inc., California Public Employees Retirement System, UBS Asset Management Americas Inc., WINTON GROUP Ltd, and BlackRock Inc..

How do I buy shares of ADC Therapeutics?

Shares of ADCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ADC Therapeutics' stock price today?

One share of ADCT stock can currently be purchased for approximately $35.85.

How big of a company is ADC Therapeutics?

ADC Therapeutics has a market capitalization of $2.47 billion.

What is ADC Therapeutics' official website?

The official website for ADC Therapeutics is www.adctherapeutics.com.

How can I contact ADC Therapeutics?

The company can be reached via phone at 41 21 653 02 00.

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.